{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:53:28Z","timestamp":1793660008616,"version":"4.5.1"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1136\/rmdopen-2026-006784","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:10:23Z","timestamp":1784117423000},"page":"e006784","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Expert viewpoint on endpoints in systemic sclerosis: current and future outlook"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-8310","authenticated-orcid":false,"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Biomedical Research Centre, Leeds Teaching Hospital Trusts, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg HW","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich-Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Cochin Hospital, Universit\u00e9 Paris Cit\u00e9, INSERM U1016, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-6390","authenticated-orcid":false,"given":"Elana J","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3161","authenticated-orcid":false,"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"},{"name":"Inflammation Fibrosis and Ageing Initiative (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[{"name":"TA Inflammation Med, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital, Ghent, Belgium"},{"name":"Department of Internal Medicine, Ghent University, Ghent, Belgium"},{"name":"Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026101405100764000_12.3.e006784.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0"},{"key":"2026101405100764000_12.3.e006784.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa026"},{"key":"2026101405100764000_12.3.e006784.3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005776","article-title":"New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025","volume":"11","author":"Sieiro Santos","year":"2025","journal-title":"RMD Open"},{"key":"2026101405100764000_12.3.e006784.4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/acr.24258","article-title":"An update of outcome measures in systemic sclerosis","volume":"72 Suppl 10","author":"Chang","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101405100764000_12.3.e006784.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219100"},{"key":"2026101405100764000_12.3.e006784.6","unstructured":"European Medicines Agency . Concept paper on the new reflection paper on the clinical investigation of medicinal products for the treatment of systemic sclerosis. Amsterdam: European Medicines Agency, 2025."},{"key":"2026101405100764000_12.3.e006784.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415160"},{"key":"2026101405100764000_12.3.e006784.8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijcard.2016.03.084","article-title":"Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis","volume":"212","author":"Vandecasteele","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026101405100764000_12.3.e006784.9","doi-asserted-by":"crossref","first-page":"v53","DOI":"10.1093\/rheumatology\/kex202","article-title":"Assessment of skin involvement in systemic sclerosis","volume":"56","author":"Kum\u00e1novics","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430"},{"key":"2026101405100764000_12.3.e006784.11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.semarthrit.2017.05.005","article-title":"High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in systemic sclerosis","volume":"47","author":"Abozaid","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2026101405100764000_12.3.e006784.12","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2665-9913(24)00334-5","article-title":"Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Fretheim","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026101405100764000_12.3.e006784.13","doi-asserted-by":"publisher","DOI":"10.1177\/23971983221083772"},{"key":"2026101405100764000_12.3.e006784.14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejim.2018.10.013","article-title":"Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study","volume":"60","author":"Bosello","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026101405100764000_12.3.e006784.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew246"},{"key":"2026101405100764000_12.3.e006784.16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.21964","article-title":"Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis","volume":"65","author":"Dor\u00e9","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101405100764000_12.3.e006784.17","first-page":"S","article-title":"Joint counts in inflammatory arthritis","volume":"32","author":"Scott","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026101405100764000_12.3.e006784.18","doi-asserted-by":"crossref","first-page":"152529","DOI":"10.1016\/j.semarthrit.2024.152529","article-title":"Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network","volume":"68","author":"Espinosa-Ortega","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026101405100764000_12.3.e006784.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg427"},{"key":"2026101405100764000_12.3.e006784.20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis-specific antibodies: Novel and classical biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026101405100764000_12.3.e006784.21","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/kex201","article-title":"Points to consider in renal involvement in systemic sclerosis","volume":"56","author":"Galluccio","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2026101405100764000_12.3.e006784.23","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S156279"},{"key":"2026101405100764000_12.3.e006784.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220702"},{"key":"2026101405100764000_12.3.e006784.25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2019-eular.3388","article-title":"FRI0334 Performance of the Scleroderma Skin Patient-Reported Outcome (SSPRO) in a phase 2 trial with lenabasum.","volume":"78","author":"Man","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026101405100764000_12.3.e006784.26","first-page":"150","article-title":"Fatigue in systemic sclerosis: a systematic review","volume":"36 Suppl 113","author":"Basta","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2026101405100764000_12.3.e006784.27","doi-asserted-by":"publisher","DOI":"10.1177\/2397198318765061"},{"key":"2026101405100764000_12.3.e006784.28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.43120","article-title":"Serum type I interferon score for prediction of clinically meaningful disease progression in limited cutaneous systemic sclerosis","volume":"77","author":"Di Donato","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026101405100764000_12.3.e006784.29","first-page":"1635","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026101405100764000_12.3.e006784.30","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/rheumatology\/keae561","article-title":"Self-reported skin severity and quality of life in systemic sclerosis: multicentre validation of PASTUL","volume":"64","author":"Spierings","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.31","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ard.2025.06.296","article-title":"POS0941 New patient-reported outcome measures for early systemic sclerosis using the FDA guidance on patient reported outcome measures","volume":"84","author":"Khanna","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026101405100764000_12.3.e006784.32","doi-asserted-by":"publisher","DOI":"10.1177\/23971983241278079"},{"key":"2026101405100764000_12.3.e006784.33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/annrheumdis-2023-eular.4633","article-title":"POS1258 Results from a nominal group technique exercise for the creation of a combined response index for limited cutaneous systemic sclerosis: the CRISTAL project","volume":"82","author":"Lescoat","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026101405100764000_12.3.e006784.34","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1093\/rheumatology\/keaf234","article-title":"The complex diagnosis of primary heart involvement in systemic sclerosis: red flags to drive the choice of cardiac magnetic resonance","volume":"64","author":"Batani","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.35","doi-asserted-by":"crossref","first-page":"152723","DOI":"10.1016\/j.semarthrit.2025.152723","article-title":"Subclinical coronary artery calcification in systemic sclerosis using high-resolution chest CT: identification, extent, and disease-specific risk factors","volume":"73","author":"N\u00e6ser","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026101405100764000_12.3.e006784.36","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30421-5"},{"key":"2026101405100764000_12.3.e006784.37","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/S2665-9913(23)00189-3","article-title":"MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study","volume":"5","author":"Hughes","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026101405100764000_12.3.e006784.38","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/art.39718","article-title":"Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: A multicenter, prospective cohort study","volume":"68","author":"Cutolo","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026101405100764000_12.3.e006784.39","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keac079","article-title":"Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement\/progression?","volume":"61","author":"Vanhaecke","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005704","article-title":"Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial","volume":"11","author":"Smith","year":"2025","journal-title":"RMD Open"},{"key":"2026101405100764000_12.3.e006784.41","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00244-7"},{"key":"2026101405100764000_12.3.e006784.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2026101405100764000_12.3.e006784.43","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/rheumatology\/keaa911","article-title":"Disease progression in systemic sclerosis","volume":"60","author":"van Leeuwen","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215145"},{"key":"2026101405100764000_12.3.e006784.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"2026101405100764000_12.3.e006784.46","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1398OC"},{"key":"2026101405100764000_12.3.e006784.47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"2026101405100764000_12.3.e006784.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2026101405100764000_12.3.e006784.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2026101405100764000_12.3.e006784.50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"2026101405100764000_12.3.e006784.51","doi-asserted-by":"publisher","DOI":"10.1177\/23971983241291923"},{"key":"2026101405100764000_12.3.e006784.52","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/rheumatology\/kead012","article-title":"A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)","volume":"62","author":"Griffiths-Jones","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026101405100764000_12.3.e006784.53","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2026101405100764000_12.3.e006784.54","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048541","article-title":"Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial","volume":"11","author":"Hoffmann-Vold","year":"2021","journal-title":"BMJ Open"},{"key":"2026101405100764000_12.3.e006784.55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209768"},{"key":"2026101405100764000_12.3.e006784.56","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/art.42939","article-title":"Development and initial validation of the novel Scleroderma Clinical Trials Consortium Activity Index","volume":"76","author":"Ross","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026101405100764000_12.3.e006784.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214764"},{"key":"2026101405100764000_12.3.e006784.58","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005999","article-title":"Cross-validation and sensitivity to change of EULAR ScleroID as a measure of function and impact of disease in patients with systemic sclerosis","volume":"11","author":"Colak","year":"2025","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:11:54Z","timestamp":1791979914000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006784"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006784","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}